This category page covers biotechnology and pharmaceutical companies developing phosphodiesterase (PDE) inhibitors for Alzheimer's disease and related neurodegenerative disorders. Phosphodiesterase inhibitors represent a promising therapeutic approach targeting cyclic nucleotide signaling pathways critical for synaptic plasticity, memory formation, and neuroprotection.
PDE inhibitors exert neuroprotective effects through multiple pathways:
...
AD PDE Inhibitor Companies
Overview
Mermaid diagram (expand to render)
This category page covers biotechnology and pharmaceutical companies developing phosphodiesterase (PDE) inhibitors for Alzheimer's disease and related neurodegenerative disorders. Phosphodiesterase inhibitors represent a promising therapeutic approach targeting cyclic nucleotide signaling pathways critical for synaptic plasticity, memory formation, and neuroprotection.
Clinical Trial: NCT05463780 — Randomized, double-blind, placebo-controlled study in mild-to-moderate AD patients[/aribio][@pde5_neuro]
Phase 2/3 Trial Design:
Primary endpoints: ADAS-Cog13, ADCS-ADL
Enrollment: patients with mild-to-moderate AD
Status: Active, recruiting
AR1002: Tau Aggregation Inhibitor
Separate program targeting tau pathology
Preclinical stage
Reference: [@aribio]
Boehringer Ingelheim — PDE Inhibitors
[Boehringer Ingelheim](/companies/boehringer-ingelheim) is developing BI 9064, a PDE inhibitor for neuroprotection.
Lead Program: BI 9064
Mechanism: Phosphodiesterase inhibition
Indication: Parkinson's disease (neuroprotection)
Stage: Preclinical
Rationale: PDE inhibition reduces neuroinflammation and supports neuronal survival
Notes: While initially developed for PD, the mechanism is applicable to AD
Reference: [@boehringer]
Eisai — PDE9 Inhibitors
[Eisai](/companies/eisai) is a Japanese pharmaceutical company with E2027, a PDE9 inhibitor in development for Alzheimer's disease.
Lead Program: E2027
Mechanism: Phosphodiesterase 9 (PDE9) inhibition
Indication: Alzheimer's disease
Stage: Phase 2
Rationale: PDE9 is enriched in the hippocampus and cortex, regions critical for memory. PDE9 inhibition enhances cGMP signaling downstream of NMDA receptor activation, promoting synaptic plasticity and memory formation[@eisai][@pde9_ad]
Key Features:
Brain-penetrant small molecule
Selective PDE9 inhibition
Once-daily oral dosing
Reference: [@eisai]
Competitive Landscape
| Company | Drug | PDE Target | Indication | Stage | |---------|------|------------|------------|-------| | AriBio | AR1001 | PDE5 | AD | Phase 2/3 | | Eisai | E2027 | PDE9 | AD | Phase 2 | | Lundbeck | Lu AF20513 | PDE4B | AD | Phase 1 | | Boehringer | BI 9064 | PDE | PD | Preclinical |
Scientific Rationale
Evidence Supporting PDE Inhibition in AD
Multiple lines of evidence support PDE inhibition as a therapeutic strategy for AD:
Elevated PDE expression: PDE4B and PDE5 are overexpressed in AD brain tissue
Reduced cGMP/cAMP signaling: Cyclic nucleotide levels are reduced in AD
Preclinical efficacy: PDE inhibitors improve memory in animal models
[Li J, et al., PDE4 inhibitors for cognitive enhancement in neurodegenerative disease. Neuropharmacology (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Baleztena et al., PDE5 Inhibitors and Neuroprotection. Frontiers in Pharmacology (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/)
[PDE9 inhibition as a therapeutic target for Alzheimer's disease. Journal of Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)